Review
Tight Junctions as Targets and Effectors of Mucosal Immune Homeostasis

https://doi.org/10.1016/j.jcmgh.2020.04.001Get rights and content
Under a Creative Commons license
open access

Defective epithelial barrier function is present in maladies including epidermal burn injury, environmental lung damage, renal tubular disease, and a range of immune-mediated and infectious intestinal disorders. When the epithelial surface is intact, the paracellular pathway between cells is sealed by the tight junction. However, permeability of tight junctions varies widely across tissues and can be markedly impacted by disease. For example, tight junctions within the skin and urinary bladder are largely impermeant and their permeability is not regulated. In contrast, tight junctions of the proximal renal tubule and intestine are selectively permeable to water and solutes on the basis of their biophysical characteristics and, in the gut, can be regulated by the immune system with remarkable specificity. Conversely, modulation of tight junction barrier conductance, especially within the gastrointestinal tract, can impact immune homeostasis and diverse pathologies. Thus, tight junctions are both effectors and targets of immune regulation. Using the gastrointestinal tract as an example, this review explores current understanding of this complex interplay between tight junctions and immunity.

Keywords

Intestinal Permeability
Barrier
Myosin Light Chain Kinase
Enteric Infection
Inflammatory Bowel Disease
Graft-Versus-Host Disease
Pore Pathway
Leak Pathway
Claudin

Abbreviations used in this paper

B6
C57BL/6
BMT
bone marrow/hematopoietic stem cell transplantation
DSS
dextran sulfate sodium
GVHD
graft-versus-host disease
IBD
inflammatory bowel disease
IL
interleukin
JAM-A
junctional adhesion molecule-A
LIGHT
lymphotoxin-like inducible protein that competes with glycoprotein D for herpesvirus entry mediator on T cells
MDCK
Madin-Darby canine kidney
MLC
myosin II regulatory light chain
MLCK
myosin light chain kinase
NK
natural killer
TER
transepithelial electrical resistance
TNF
tumor necrosis factor
ZO
zonula occludens

Cited by (0)

Author contributions Li Zuo: conceptualization, equal; funding acquisition, supporting; writing original draft, lead; writing review and editing, equal. Wei-Ting Kuo: conceptualization, equal; writing original draft, equal; writing review and editing, equal. Jerrold R. Turner: conceptualization, lead; funding acquisition, lead; writing original draft, lead.

Conflicts of interest This author discloses the following: Jerrold R. Turner is a co-founder of Thelium Therapeutics, Inc. The remaining authors disclose no conflicts.

Funding This work was supported by NIH grants R01DK61931 (JRT), R01DK68271 (JRT), and R24DK099803 (JRT); the Harvard Digestive Disease Center (P30DK034854); the Department of Defense CDMRP PR181271 (JRT); and by National Natural Science Foundation of China grant 81800464 (LZ).

These authors contributed equally.